Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | LIPA | P38571 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1958414 | 1.00 | CES2 (0.38) | CES2LMNAESR1CYP3A4CYP2C9 | |
| SCHEMBL9815832 | 0.84 | ESR1 (0.35) | ESR1CYP3A4CYP2C9ESR2LIPA | |
| SCHEMBL5194752 | 0.82 | LIPA (0.47) | ESR1CYP3A4CYP2C9ESR2LIPA | |
| SCHEMBL10888768 | 0.82 | LIPA (0.47) | ESR1CYP3A4CYP2C9ESR2LIPA | |
| SCHEMBL9815771 | 0.82 | ESR1 (0.34) | ESR1CYP3A4CYP2C9ESR2LIPA | |
| SCHEMBL5194764 | 0.82 | LIPA (0.47) | ESR1CYP3A4CYP2C9ESR2LIPA | |
| SCHEMBL7526154 | 0.81 | LMNA (0.42) | CES2LMNA | |
| SCHEMBL456619 | 0.81 | — | — | |
| SCHEMBL8397118 | 0.80 | CES2 (0.34) | CES2LMNALIPA | |
| SCHEMBL102180 | 0.80 | THRA (0.44) | CES2LMNALIPA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4543429-A | PERFUMES | FIRMENICH SA (CH) | 1985-09-24 | — | — | US | claimed |
| EP-0092031-B1 | 1(7)P-MENTHENE-9-AL AND ITS USE AS A PERFUMING AND FLAVOURING AGENT | FIRMENICH SA (CH) | 1984-12-27 | — | — | EP | claimed |
| EP-0092031-A1 | 1(7)p-Menthene-9-al and its use as a perfuming and flavouring agent | FIRMENICH SA (CH) | 1983-10-26 | — | — | EP | claimed |
| CN-114174263-B | Non-lysosomal glucosylceramidase inhibitors and uses thereof | 阿勒克图治疗公司 | 2025-01-10 | — | — | CN | disclosed |
| EP-3966199-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | Alectos Therapeutics Inc. (CA) | 2022-03-16 | — | — | EP | disclosed |
| CN-114174263-A | Non-lysosomal glucosylceramidase inhibitors and uses thereof | 阿勒克图治疗公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-2507229-B1 | SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBVIE INC (US) | 2016-10-05 | — | — | EP | disclosed |
| CN-102947285-B | Sulfonamide derivatives as BCL-2-selective apoptosis inducers for the treatment of cancer and immune diseases | ABBVIE (US) | 2015-08-26 | — | — | CN | disclosed |
| US-9073855-B2 | BCL-2 selective apoptosis-inducing agents for the treatment of cancer and immune diseases | ABBVIE INC. (US) | 2015-07-07 | — | — | US | disclosed |
| US-9045420-B2 | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | ABBVIE INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140107119-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBVIE INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20100298321-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | US | disclosed |
| CN-101815710-A | Pyrimidine and pyridine derivatives, their pharmaceutical use and compositions | PFIZER | 2010-08-25 | — | — | CN | disclosed |
| EP-2185537-A1 | PYRIMIDINE AND PYRIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | Pfizer Inc. (US) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009016498-A1 | PYRIMIDINE AND PYRIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-4578277-A | 1(7)-p-Menthen-9-al and its utilization as perfuming and flavoring ingredient | FIRMENICH SA (CH) | 1986-03-25 | — | — | US | disclosed |
| US-4543429-A | PERFUMES | FIRMENICH SA (CH) | 1985-09-24 | — | — | US | disclosed |
| EP-0092031-B1 | 1(7)P-MENTHENE-9-AL AND ITS USE AS A PERFUMING AND FLAVOURING AGENT | FIRMENICH SA (CH) | 1984-12-27 | — | — | EP | disclosed |
| EP-0092031-A1 | 1(7)p-Menthene-9-al and its use as a perfuming and flavouring agent | FIRMENICH SA (CH) | 1983-10-26 | — | — | EP | disclosed |
| EP-0092031-A1 | 1(7)p-Menthene-9-al and its use as a perfuming and flavouring agent | FIRMENICH SA (CH) | 1983-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107119-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | BCL2, BCL3, BCL2L1 | CES2 3806/4885LMNA 2377/4885ESR1 3868/4885 |
| US-20100298321-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | BCL2, BCL3, BCL2L1 | CES2 3806/4885LMNA 2377/4885ESR1 3868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.